The Fentanyl System Shock – Are There Lessons to Learn From the COVID-19 System Shock Framework?; Comment on “The COVID-19 System Shock Framework: Capturing Health System Innovation During the COVID-19 Pandemic”

Document Type : Commentary

Authors

1 University Psychiatric Clinics Basel, University of Basel, Basel, Switzerland

2 Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada

Abstract

The Sydney Children’s Hospitals Network (SCHN) addressed the challenges of the COVID-19 pandemic by implementing innovative changes which made their health system resilient and responsive. For other healthcare systems, there are important takeaways. In the United States and Canada, an urgent widespread response is needed to address the overdose crisis, driven by potent synthetic opioids (ie, fentanyl and its derivates). We project the COVID-19 System Shock Framework (CSSF) on to the North American healthcare systems and suggest a Fentanyl System Shock Framework, which provides a framework for necessary changes and innovations to address the overdose crisis. To become resilient to the fentanyl system shock, core components as well as overarching values, health policy, and online technologies need to be adapted to reduce the death count and meet the evolving needs of marginalised individuals who use opioid. Future research should focus on scientifically assessing such implementations to guide evidence-based decision making.

Keywords

Main Subjects

References

  1. Hodgins M, van Leeuwen D, Braithwaite J, et al. The COVID-19 system shock framework: capturing health system innovation during the COVID-19 pandemic. Int J Health Policy Manag. 2021;11(10):2155-2165. doi:34172/ijhpm.2021.130
  2. Hanefeld J, Mayhew S, Legido-Quigley H, et al. Towards an understanding of resilience: responding to health systems shocks. Health Policy Plan. 2018;33(3):355-367. doi:1093/heapol/czx183
  3. Ahmad F, Rossen L, Sutton P. Provisional Drug Overdose Death Counts. National Center for Health Statistics; 2021.
  4. Humphreys K, Shover CL, Andrews CM, et al. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission. Lancet. 2022;399(10324):555-604. doi:1016/s0140-6736(21)02252-2
  5. Azar P, Westenberg JN, Ignaszewski MJ, et al. Case report: acute care management of severe opioid withdrawal with IV fentanyl. Addict Sci Clin Pract. 2022;17(1):22. doi:1186/s13722-022-00305-6
  6. Krausz RM, Westenberg JN, Mathew N, et al. Shifting North American drug markets and challenges for the system of care. Int J Ment Health Syst. 2021;15(1):86. doi:1186/s13033-021-00512-9
  7. Krausz RM, Westenberg JN, Vogel M. Addressing fentanyl use disorder with fentanyl-assisted treatment. Lancet Psychiatry. 2022;9(2):103-105. doi:1016/s2215-0366(21)00393-x
  8. Kelly TM, Daley DC. Integrated treatment of substance use and psychiatric disorders. Soc Work Public Health. 2013;28(3-4):388-406. doi:1080/19371918.2013.774673
  9. Risk Assessment and Management Platform (RAMP). https://ramp2.walkalong.ca/. Accessed May 24, 2022.
  10. Bains C. $3.5M in Funding for ‘Vending Machines’ That Dispense Safer Drugs to Prevent Ods. The Canadian Press; 2021. https://globalnews.ca/news/7674061/mysafe-drug-vending-machines-opioids/.  Accessed May 21, 2022.
  11. Meyer M, Rist B, Strasser J, et al. Exploring why patients in heroin-assisted treatment are getting incarcerated-a qualitative study. BMC Psychiatry. 2022;22(1):169. doi:1186/s12888-022-03814-5
  12. Byford S, Barrett B, Metrebian N, et al. Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. Br J Psychiatry. 2013;203(5):341-349. doi:1192/bjp.bp.112.111583
  13. Meyer M, Strasser J, Köck P, Walter M, Vogel M, Dürsteler KM. Experiences with take-home dosing in heroin-assisted treatment in Switzerland during the COVID-19 pandemic-Is an update of legal restrictions warranted? Int J Drug Policy. 2022;101:103548. doi:1016/j.drugpo.2021.103548
  14. Oviedo-Joekes E, MacDonald S, Boissonneault C, Harper K. Take home injectable opioids for opioid use disorder during and after the COVID-19 pandemic is in urgent need: a case study. Subst Abuse Treat Prev Policy. 2021;16(1):22. doi:1186/s13011-021-00358-x
  15. Panagiotoglou D. Evaluating the population-level effects of overdose prevention sites and supervised consumption sites in British Columbia, Canada: controlled interrupted time series. PLoS One. 2022; 17(3):e0265665. doi:1371/journal.pone.0265665

Files

History

  • Receive Date: 24 May 2022
  • Revise Date: 09 February 2023
  • Accept Date: 13 February 2023
  • First Publish Date: 14 February 2023

Share

How to cite

Statistics